SCHEMBL9212957

SCHEMBL9212957

CCCCC#CCCCCCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.58
HMGCR P04035 3/20 0.58
TSHR P16473 2/20 0.53
THRB P10828 1/20 0.53
RECQL P46063 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
MCL1 Q07820 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
RAB9A P51151 1/20 0.46
EPHX2 P34913 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9943932 1.00 PTPN7 (0.58) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL9210913 1.00 PTPN7 (0.58) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL9210005 1.00 PTPN7 (0.58) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL6461207 1.00 PTPN7 (0.58) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL9213049 1.00 PTPN7 (0.58) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL11061073 1.00 PTPN7 (0.58) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL23040316 0.97 PTPN7 (0.61) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL1523678 0.97 PTPN7 (0.61) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL11175213 0.97 PTPN7 (0.61) PTPN7HMGCRTSHRTHRBRECQL
SCHEMBL10796010 0.97 PTPN7 (0.61) PTPN7HMGCRTSHRTHRBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US claimed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP claimed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO claimed
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO claimed
WO-2023225621-A2 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS OMEGA THERAPEUTICS, INC. (US) 2023-11-23 WO claimed
EP-1753708-B1 NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME UNIV BRIGHAM YOUNG (US) 2018-02-21 EP claimed
EP-2181763-B1 Catalyst and process for alkoxylation SHELL INT RESEARCH (NL) 2012-06-20 EP claimed
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US disclosed
EP-3881048-B1 DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS LETAT FRANCAIS REPRESENTE PAR LE MINI DE LINTERIEUR (FR) 2026-05-06 EP disclosed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP disclosed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
WO-2023225621-A2 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS OMEGA THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
CN-105074994-B Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same 三菱化学株式会社 2018-10-19 CN disclosed
CN-108290992-A POLYURETHANE/UREA MATERIALS 联邦科学和工业研究组织 2018-07-17 CN disclosed
CN-107078352-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2017-08-18 CN disclosed
CN-102137593-A Pesticidal mixtures comprising cyanosulfoximine compounds and spinetoram BASF SE 2011-07-27 CN disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS NSUN3, NSUN2, LDLR PTPN7 2194/4885HMGCR 460/4885TSHR 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.